小肠神经内分泌肿瘤淋巴结转移预后作用及准确分期所需最少淋巴结数
该多中心病例系列纳入199例2000-2015年间行根治性原发灶切除的小肠神经内分泌肿瘤患者,分析淋巴结阳性及检出淋巴结数对无复发生存的影响。结果显示,检出至少8枚淋巴结才能准确区分4枚及以上、1-3枚及0枚阳性患者的3年无复发生存,且4枚及以上阳性者预后更差。
要点
- 准确分期小肠神经内分泌肿瘤需至少检出8枚淋巴结。
- 4枚及以上淋巴结阳性者3年无复发生存较0-3枚阳性者更差。
- 彻底的区域淋巴结清扫对准确分期和管理可能至关重要。
核心结论
- 根治性切除小肠神经内分泌肿瘤时,准确淋巴结分期需至少检查8枚淋巴结。
- 4枚及以上阳性淋巴结与1-3枚或0枚阳性相比,3年无复发生存降低。
研究设计与样本
- 美国神经内分泌肿瘤研究组多中心病例系列,纳入8家学术三级转诊中心199例患者。
- 纳入2000年1月1日至2015年12月31日间行根治性原发灶切除的小肠神经内分泌肿瘤患者。
- 排除十二指肠或壶腹部肿瘤、合并非神经内分泌恶性肿瘤、术后30天内死亡及远处转移者。
主要发现
- 199例中男性112例(56.3%),女性87例(43.7%),平均年龄60.3岁(SD 12.5)。
- 淋巴结阳性与阴性患者3年无复发生存无差异。
临床怎么用
- 行根治性切除时应追求至少检出8枚淋巴结以准确分期。
- 发现4枚及以上阳性淋巴结提示复发风险较高,需加强随访。
局限性
- 为回顾性病例系列,假设在数据收集后生成。
- 样本来自8家学术中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Little information is available regarding the minimum number of lymph nodes needed to accurately stage patients when performing a mesenteric lymphadenectomy for small-bowel neuroendocrine tumors. OBJECTIVES: To determine the prognostic role of lymph node positivity and the ideal number of lymph nodes for accurately staging patients with small-bowel neuroendocrine tumors. DESIGN, SETTING, AND PARTICIPANTS: This case series from the US Neuroendocrine Tumor Study Group, a collaboration among 8 US-based, academic tertiary care referral centers, obtained demographic, perioperative, and pathologic data from the group's database, Social Security Death Index, and publicly available obituaries. All patients in these institutions with small-bowel neuroendocrine tumors who underwent curative-intent surgical resection of a primary tumor between January 1, 2000, and December 31, 2015, were included (n = 199). Patients with duodenal or ampullary tumors, other nonneuroendocrine concurrent malignant neoplasms, mortality of fewer than 30 days after the surgical procedure, and distant metastatic disease were excluded. Data analysis was conducted from September 1, 2017, to December 1, 2017. MAIN OUTCOMES AND MEASURES: Primary study outcome was recurrence-free survival. Hypothesis was generated after data collection and data entry into the US Neuroendocrine Tumor Study Group database. RESULTS: Of the 199 patients included, 112 (56.3%) were male and 87 (43.7%) female with a mean (SD) age of 60.3 (12.5) years and a mean (SD) body mass index of 29.5 (6.0). One hundred fifty-four patients (77.4%) had lymph node-positive disease. No difference in 3-year recurrence-free survival was found between patients with lymph node-positive and lymph node-negative disease. Patients with 4 positive lymph nodes had a worse 3-year recurrence-free survival compared with those with 1 to 3 or 0 positive lymph nodes (81.6% vs 91.4% vs 92.1%; P = .01). When examining patients with fewer than 8 resected lymph nodes, no difference in 3-year recurrence-free survival was observed among patients with 4 or more, 1 to 3, or 0 positive lymph nodes (100% vs 93.8% vs 91.7%; P = .87). Retrieval of 8 or more lymph nodes, however, accurately discriminated patients with 4 or more, 1 to 3, or 0 positive lymph nodes (3-year recurrence-free survival: 79.9% vs 89.6% vs 92.9%; P = .05). CONCLUSIONS AND RELEVANCE: The findings from this study suggest that, for patients undergoing curative-intent resection of small-bowel neuroendocrine tumors, accurate lymph node staging requires a minimum of 8 lymph nodes for examination, and 4 or more positive lymph nodes are associated with decreased 3-year recurrence-free survival compared with 1 to 3 or 0 positive lymph nodes; a thorough regional lymphadenectomy may be critical for accurate staging and management of this disease.
引用
- Zaidi MY, Lopez-Aguiar AG, Dillhoff M, et al. Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. JAMA Surg. 2019. PMID: 30383112. doi:10.1001/jamasurg.2018.3865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。